Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema.

Background/aims: The RELIGHT clinical trial used an individualised treatment regimen of ranibizumab to treat diabetic macular oedema (DMO). We report findings from two patient-reported outcome instruments.
Methods: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was administered before starting treatment (M0) and at M6, 12 and 18. The Macular Disease Society Treatment Satisfaction Questionnaire (MacTSQ) was administered 1 month after treatment start (M1) and at M6, 12 and 18. Relationships between best-corrected visual acuity (BCVA) in the study eye (SE) and the status of the eye at baseline (as better or worse eye by BCVA) and the two instrument measures were investigated.
Results: BCVA in the SE correlated strongly with the NEI-VFQ composite scores and the majority of the subscales but not with the MacTSQ subscales. Statistically significant improvements were observed in the majority of the subscales of the NEI-VFQ at M6, 12 and 18. For the MacTSQ, improvements between baseline M6, 12 and 18 were seen for subscale 1 but only reached statistical significance at M12. In subscale 2, the changes in mean scores were statistically significant at all timepoints.
Conclusions: Although ranibizumab treatment in DMO over an 18-month period resulted in improvements in visual functioning and patient satisfaction, no correlation was found between the instruments used to measure these outcomes. Our finding of a lack of correlation between BCVA and the MacTSQ suggests the presence of psychophysical factors not measured by traditional means.
Competing Interests: Competing interests: UC reports grants and personal fees from Novartis and Bayer Pharma. IP reports lecture fees and consulting fees from Novartis. RG reports lecture fees and grants from Novartis. SS reports grants and personal fees from Novartis, Bayer, Roche, Boehringer Ingelheim, Optos and Heidelberg. LD reports personal fees from Novartis, Bayer, Alimera and Allergan. BJLB reports grants and research funding from Novartis Pharma. SP reports other from Novartis, Bayer, Allergan and Alimera. SL reports other from Novartis. JP and SB have nothing to disclose.